Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
05/17/2012 | 07:41pm CEST
   By Peter Loftus 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
06:32a JOHNSON & JOHNSON : West African health practitioners build capacity
10/14 JOHNSON & JOHNSON : Janssen announces u.s. fda approval of stelara® (ustekinumab..
10/13 JOHNSON & JOHNSON : CHMP Issues a Positive Opinion on Janssen's ZYTIGA® to Inclu..
10/13 JOHNSON & JOHNSON : Richard McDonald
10/12 JOHNSON & JOHNSON : Announces Completion of Codman Neurosurgery Divestiture to I..
10/12 JOHNSON & JOHNSON : U.S. Supreme Court Turns Back Appeal of $3.27 Million Ethico..
10/12JOHNSON & JOHNSON : quaterly earnings release
10/12 JOHNSON & JOHNSON : DOH, J and J join hands to address health concerns of BPO wo..
10/11 Kroger and JetBlue rise while Coach and Sears slump
10/11 MARKETS RIGHT NOW : Modest gains for stocks set more records
More news
News from SeekingAlpha
10/16 Avoid This Credit Card And Travel Services Company With Poor Total Return
10/16 EDITORS' PICKS DAILY : Investors Overhyping Amazon-Whole Foods, REIT Picks & Wee..
10/16 Notable earnings before Tuesday?s open
10/16 Take Profits On Johnson & Johnson
10/16 YOUR DAILY PHARMA SCOOP : ACRX Second Chance, AERI Rhopressa Success, Aratana EN..
Financials ($)
Sales 2017 75 835 M
EBIT 2017 22 920 M
Net income 2017 16 692 M
Debt 2017 17 591 M
Yield 2017 2,46%
P/E ratio 2017 22,37
P/E ratio 2018 18,39
EV / Sales 2017 5,05x
EV / Sales 2018 4,68x
Capitalization 365 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 138 $
Spread / Average Target 1,7%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265
AMGEN25.17%132 728